Literature DB >> 12050514

Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder.

Sajal C Dutta1, Sam C Chang, Christopher S Coffey, Joseph A Smith, Gregory Jack, Michael S Cookson.   

Abstract

PURPOSE: Health related quality of life after urinary diversion has been increasingly recognized as an important outcome measure. However, few studies have directly compared patients with an ileal conduit with those with a continent orthotopic neobladder and even fewer have used validated quality of life instruments. Therefore, we compared health related quality of life in patients who underwent neobladder versus ileal conduit creation using validated questionnaires.
MATERIALS AND METHODS: We mailed 2 validated questionnaires that are measures of health related quality of life, namely the RAND 36-Item Health Survey (SF-36) and Functional Assessment of Cancer Therapy-General (FACT-G), to patients who underwent radical cystectomy for urothelial carcinoma between January 1995 and December 1999. Statistical analysis was performed, including univariate and multivariate analysis.
RESULTS: A total of 112 patients were available for assessment. A total of 72 (64%) questionnaires were returned, including 23 (32%) and 49 (68%) from patients with an ileal conduit and neobladder, respectively. On the SF-36 questionnaire there were significant univariable relationships between treatment and age (p <0.001 and 0.01, respectively). Younger patients and those with a neobladder had higher health related quality of life scores, including significant differences in 5 of the 9 SF-36 domains (general health, physical functioning, physical health, social functioning and energy/fatigue). There was no relationship between health related quality of life and the final pathological stage (p = 0.25). On multivariate analysis adjusting for age led to a suggestive but nonsignificant difference in health related quality of life scores favoring neobladders (p = 0.09). On the FACT-G there were no significant differences in health related quality of life due to treatment (p = 0.28), pathological stage (p = 0.5), age (p = 0.72) or current disease status (p = 0.27). On the FACT-G 2 of the 4 domains (emotional and functional well-being) were significantly in favor of neobladders. Overall satisfaction was high in the 2 groups with 96% and 85% of patients with a neobladder and ileal conduit, respectively, reporting that they would make the same choice of diversion.
CONCLUSIONS: Based on validated health related quality of life instruments these findings suggest that patients with an orthotopic neobladder have marginal quality of life advantages over those with an ileal conduit. However, differences in health related quality of life in the 2 types of urinary diversion are confounded by age since patients who underwent orthotopic diversion were younger and as a result of age would be expected to have a higher health related quality of life score. A prospective longitudinal study of health related quality of life after adjusting for differences in age among patients undergoing urinary diversion is currently underway to extend further these observations.

Entities:  

Mesh:

Year:  2002        PMID: 12050514

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  44 in total

1.  [Radical cystectomy in the treatment of bladder cancer always in due time?].

Authors:  M May; K-P Braun; W Richter; C Helke; H Vogler; B Hoschke; M Siegsmund
Journal:  Urologe A       Date:  2007-08       Impact factor: 0.639

Review 2.  [Quality of life after radical urologic pelvic surgery and impact of inpatient rehabilitation].

Authors:  O Dombo; U Otto
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

3.  [Urinary diversion after cystectomy: aspects of quality of life and options for rehabilitation].

Authors:  M Zellner; R Riedl
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

4.  Which urinary diversion is best after radical cystectomy? The case for "incontinent" diversion.

Authors:  Michael J Leveridge; Michael A S Jewett
Journal:  Can Urol Assoc J       Date:  2008-08       Impact factor: 1.862

5.  Determining when to recommend continent urinary diversion.

Authors:  Scott M Gilbert; James E Montie
Journal:  Can Urol Assoc J       Date:  2008-08       Impact factor: 1.862

6.  Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.

Authors:  Hangchuan Shi; Han Yu; Joaquim Bellmunt; Jeffrey J Leow; Xuanyu Chen; Changcheng Guo; Hongmei Yang; Xiaoping Zhang
Journal:  Qual Life Res       Date:  2018-06-20       Impact factor: 4.147

Review 7.  Bladder Cancer Survivorship.

Authors:  Sumeet K Bhanvadia
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

Review 8.  Is Health-Related Quality of Life after Radical Cystectomy Using Validated Questionnaires Really Better in Patients with Ileal Orthotopic Neobladder Compared to Ileal Conduit: A Meta-Analysis of Retrospective Comparative Studies.

Authors:  Maria A Cerruto; Carolina D'Elia; Salvatore Siracusano; Antonio B Porcaro; Giovanni Cacciamani; Davide De Marchi; Mauro Niero; Cristina Lonardi; Massimo Iafrate; Pierfrancesco Bassi; Emanuele Belgrano; Ciro Imbimbo; Marco Racioppi; Renato Talamini; Stefano Ciciliato; Laura Toffoli; Michele Rizzo; Francesco Visalli; Paolo Verze; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

9.  Factors associated with non-orthotopic urinary diversion after radical cystectomy.

Authors:  In Gab Jeong; Dalsan You; Jongwon Kim; Seong Cheol Kim; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  World J Urol       Date:  2012-03-07       Impact factor: 4.226

Review 10.  Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Curr Urol Rep       Date:  2018-10-24       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.